Dr. Brandwein is currently Division Director, Professor of Medicine in the Division of Hematology at the University of Alberta, Department of Medicine and Adjunct Professor in the Department of Oncology. He graduated from McGill University Medical School in 1983 and completed his internal medicine residency at Dalhousie University in Halifax, followed by a hematology residency in Vancouver. He then completed a research fellowship in leukemia and autologous bone marrow transplantation at the Toronto General Hospital.
He worked as an academic clinical hematologist at St. Michael’s Hospital in Toronto for nearly ten years. From 2000-2013, he was a clinical investigator in the Department of Medical Oncology and Hematology at Princess Margaret Hospital/University Health Network in Toronto. He joined the faculty at the University of Alberta in August, 2013.
His major academic focus has been clinical research in acute leukemias and related hematologic malignancies. He has completed a number of investigator-initiated clinical studies evaluating novel treatments for leukemia, and performed extensive evaluations of prognostic factors in AML and ALL. He has well over 100 peer-reviewed publications in this area, and has been an invited speaker at numerous meetings, including the American Society of Hematology. He was the NCIC National Chair of an international clinical trial in AML, and was also the chair and lead author of a national group of leukemia experts that developed consensus guidelines for the treatment of AML in the elderly.
Dr. Brandwein has been heavily involved in undergraduate and postgraduate training for many years. He developed a Leukemia Fellowship Program at Princess Margaret Hospital that attracted numerous trainees from around the world, and was also the coordinator of preclinical undergraduate hematology teaching at the University of Toronto. He also built a clinical research program in leukemia at Princess Margaret Hospital, and has assumed the role of chair of the Hematology Clinical Research Program at the University of Alberta Hospital. His research efforts are now directed toward the pre-clinical and early clinical evaluation of potential new therapeutic approaches in acute leukemia, with a focus on understanding mechanisms of drug resistance and circumventing these, in collaboration with other researchers at the University.
acute myeloid leukemia, apoptosis, chemotherapy, Clinical trial, DNA repair, drug resistance, leukemia, Quality of life analysis